Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03964220 · ClinicalTrials.gov registry record
Impact of Tiotropium Add-on Therapy in Patients With Asthma
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 7,857
- Enrollment target
NCT03964220 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 7,857 participants.
The verdict
NCT03964220 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 7,857 participants
- Enrollment target
Study Summary
To evaluate the effectiveness of add on therapy with Tiotropium Respimat® compared to increasing the dose of ICS in patients with a diagnosis of Asthma and on ICS/LABA therapy
Interventions
- DRUG Tiotropium Respimat®
- DRUG Inhaled Corticosteroid/Long-acting beta-agonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,857 participants |
| Start Date | 2019-03-15 |
| Est. Completion | 2019-09-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03964220
The ClinicalTrials.gov registry entry for NCT03964220 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7,857 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tiotropium Respimat® is the first listed.
NCT03964220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03964220 about?
NCT03964220 is a clinical study titled "Impact of Tiotropium Add-on Therapy in Patients With Asthma". To evaluate the effectiveness of add on therapy with Tiotropium Respimat® compared to increasing the dose of ICS in patients with a diagnosis of Asthma and on ICS/LABA therapy
What is the current status of trial NCT03964220?
This trial is currently completed. The enrollment target is 7,857 participants. The study started on 2019-03-15. Estimated completion is 2019-09-20.
What interventions are being tested in trial NCT03964220?
The interventions under investigation include: Tiotropium Respimat® (DRUG), Inhaled Corticosteroid/Long-acting beta-agonist (DRUG).
Who is sponsoring clinical trial NCT03964220?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.